Analytical methods
Genomic sequencing of coding exons and flanking intronic sequences. dHPLC and HRM may also apply.
Analytical validation
Confirmation of mutation in an independent biological sample of the index case and/or in an affected subject; segregation analysis in the parents of the index patient.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) 1:30 000-1:50 000. 1 1.9 If applicable, prevalence in the ethnic group of investigated person Unknown.
Diagnostic setting

Comment:
As penetrance is 100% and since disease is present from birth, the test is not used for predictive testing. It is 75-90% 2-4 depending on population -there is evidence for further genetic heterogeneity.
TEST CHARACTERISTICS
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Above 95%.
Positive clinical predictive value (life-time risk to develop the disease if the test is positive)
Although clinical expression can vary (complete and incomplete achromatopsia, rarely cone dystrophy and macular degeneration), the condition is expected to be 100% penetrant. 
.4). If the test result is negative (please describe):
This will lead to reconsider the clinical diagnosis. The diagnosis of achromatopsia will therefore be either confirmed, suggesting a rare genetic form (genetic heterogeneity) for which the causative gene remains unknown, or excluded and redirected to for example, blue cone monochromacy.
Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?
Regular ophthalmological follow-up examination.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked) 
